🇺🇸 FDA
Patent

US 11472842

Analogues of hepcidin mimetics with improved in vivo half lives

granted A61KA61K38/00A61P

Quick answer

US patent 11472842 (Analogues of hepcidin mimetics with improved in vivo half lives) held by Protagonist Therapeutics, Inc. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Protagonist Therapeutics, Inc.
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61P, A61P3/02